Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

Bullboard (TSXV:TLT)

View:
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
Comment by TommyNickelson Nov 29, 2024 6:36pm

RE:Cash Infusion

Roger needs millions. End of story. He'll be looking for another PP  shortly.  20 cents?. Maybe he raises another 600,000.  Another 30 days?
20
Discussion
Comment by skier59on Nov 29, 2024 6:30pm

RE:RE:RE:Pioneering is never easy...

That is the most baseless, ridiculous accusation. He is a person of ethics and respectable values. Unlike your MAGA Leader.
33
Discussion
Comment by TommyNickelson Nov 29, 2024 6:29pm

RE:RE:RE:RE:RE:Still no takers

Your anger should be directed at Roger. Now 22 cents and heading lower. This was all predictable. 
20
Discussion
Comment by TommyNickelson Nov 29, 2024 6:23pm

RE:20% discount

Once it hits the teens, I'll consider again.  Problem is that Roger is fast and loose with the truth so proceeding with caution necessary. 
22
Discussion
Post by TriumphSpitSixon Nov 29, 2024 5:59pm

FDA is utterly corrupt!

Forget "fast track" and "accelerated approval." The US FDA hyper-tracked and even created entirely new programs just to push their handlers' covid vax poisons on us with very ...more  
92
Comment by DeathXray33on Nov 29, 2024 5:27pm

RE:RE:RE:RE:RE:RE:RE:RE:RE:Level II Quotes ! Big Drop This AM

I'm doing the same. -------------------------------------------------------------"The activation of Rutherrin by Metformin is a game changer in the clinical use of Rutherrin. By activating it ...more  
78
Discussion
Post by rhodiumdon Nov 29, 2024 5:20pm

Theralase continue to advance bladder cancer study during Q3

Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) continued to make progress in its Study II clinical trial, which focuses on the treatment of BCG-unresponsive non-muscle invasive bladder ...more  
118
Comment by Dumbeldorfwhiteon Nov 29, 2024 5:03pm

RE:RE:RE:RE:Maybe the FDA is looking at the side effects

And to further elaborate that's 11/75 people with severe adverse reactions which is quite a high number. No wonder the FDA wants more information 
29
Discussion
Comment by Dumbeldorfwhiteon Nov 29, 2024 5:00pm

RE:RE:RE:Maybe the FDA is looking at the side effects

No no I'm not buying it. N803 and BCG are both instilled and were a direct comparison. 7 AEs grade 3 out of 75 patients. While n803 had 3 in double the patients.
27
Discussion
Comment by CAinPlapon Nov 29, 2024 4:26pm

RE:RE:Pioneering is never easy...

I don't think NotaPoop is in the same class as Dumdum and woodennickel. My WAG is he may be Bunge. :)
48
Discussion
Comment by bmk211on Nov 29, 2024 3:20pm

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Level II Quotes ! Big Drop This AM

Not manipulating.  Using the inversion technique to try to understand the waters ahead.
56
Discussion
Comment by enriquesuaveon Nov 29, 2024 2:47pm

RE:RE:Maybe the FDA is looking at the side effects

No adverse event related to drug or treatment.  Only to procedure of instillation which is the same for any instilled drug. 
73
Discussion
Comment by Dumbeldorfwhiteon Nov 29, 2024 2:44pm

RE:Maybe the FDA is looking at the side effects

3 grade threes in a cohort twice the size vs  7 out of 75     A "Grade 3 adverse event" related to the bladder refers to a severe complication that ...more  
76
Discussion
Comment by Dumbeldorfwhiteon Nov 29, 2024 2:39pm

RE:Riddle me this !

Well cuz u and skier keep voting in JT.
44
Discussion
Post by Dumbeldorfwhiteon Nov 29, 2024 2:38pm

Maybe the FDA is looking at the side effects

U know for a treatment being said is 100 % safe, it sure looks like there are more sides than n803 Most treatment-emergent adverse events for patients receiving BCG plus NAI were grade 1 to 2 (86%) ...more  
100
Discussion
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT

Visit Facebook Visit X Visit Linked In Visit Instagram Visit Youtube



INVESTORS & MEDIA OVERVIEW FINANCIAL FILINGS PRESENTATIONS MEDIA FACT SHEETS MANAGEMENT

Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250